A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Dose, Dose Ranging Study to Evaluate Up to Three Doses of R935788 in Rheumatoid Arthritis Patients Failing to Respond to Methotrexate

Rigel Pharmaceuticals38 sites in 2 countries189 target enrollmentAugust 2006

ConditionsRheumatoid Arthritis

InterventionsR788 Placebo

DrugsR788 Placebo

Overview

Phase: Phase 2
Intervention: R788
Conditions: Rheumatoid Arthritis
Sponsor: Rigel Pharmaceuticals
Enrollment: 189
Locations: 38
Primary Endpoint: The Primary Efficacy parameter is ACR20 response rate at 3 months post dosing.
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled, ascending dose, dose ranging study to evaluate up to three doses of R935788 (50 mg bid, 100 mg bid and 150 mg bid). Approximately 180 patients who have had rheumatoid arthritis for a minimum of 12 months and who have been receiving a weekly methotrexate (MTX) dose for a minimum of 6 months will be enrolled into the study.

Detailed Description

The primary objective of this study is to assess the preliminary efficacy of up to three different dosage regimens of R788 as determined by ACR 20 responder rates at 12 weeks The secondary objectives of this study are to assess the safety of up to three different dosage regimens of R788 as determined by ACR 20 responder rates at 12 weeks, and to assess the general clinical and laboratory safety evaluations throughout the study.

Registry

clinicaltrials.gov

Start Date

August 2006

End Date

December 2007

Last Updated

17 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Rigel Pharmaceuticals

Eligibility Criteria

Inclusion Criteria

•Patients must give written informed consent by signing an IRB-approved Informed Consent Form (ICF) prior to admission to this study.
•Males and females, 18 to 75 years of age, with active RA for at least 12 months (functional class I-III, e.g., not bed or wheelchair-bound) who have been receiving weekly doses of methotrexate (10-25 mg/week) for a minimum of 180 days, and who have been receiving a stable MTX dose of at least 15 mg without any change in route or change in folic acid supplementation for at least 30 days.
•Active RA is defined as the presence of (a)6 swollen joints (28 joint count); AND (b)6 tender joints (28 joint count); AND (c) CRP level \> ULN for the central reference laboratory.
•Patient may receive up to 10 mg per day of oral prednisone or steroid equivalent, NSAID therapy, hydroxychloroquine, chloroquine, minocycline, sulfasalazine, and doxycycline. The dose(s) must have been stable for at least 30 days and must not be changed during the washout, screening and treatment periods, unless dictated by tolerability requirements.
•Females of childbearing potential must be fully informed of the potential for methotrexate and R788 to adversely affect the fetus and must agree to use adequate (2 methods) contraception during the study. These patients must not be lactating and must have a negative urine pregnancy test at the time of randomization and at each laboratory determination.
•The patient is in otherwise good health as determined by the Investigator on the basis of medical history, physical examination, and laboratory screening tests during the screening period, including the absence of clinically significant findings, such as HIV, HBV or HCV, interstitial pneumonitis or active pulmonary infection, on chest X-ray taken within 6 months prior to screening and a negative TB skin test, or abnormal liver function defined as known ALT \>1.2xULN within the past 90 days.
•In the investigator's opinion, the patient has the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the investigator and to participate in, and to comply with, the requirements of the entire protocol.

Exclusion Criteria

•The patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the Investigator's opinion, could affect the conduct of the study (these will be included in an exclusion log).
•The patient has a history of substance abuse, drug addiction or alcoholism.
•The patient is unable to abstain from alcohol during the study.
•The patient has a recent (past 5 years) history of, or treatment for, a malignancy other than basal skin cancer.
•The patient has received any investigational medication within 30 days prior to admission to the study.
•Any patient who has received any of the following treatments must abide by the indicated washout period:
•oral or injectable gold, azathioprine, penicillamine, anakinra require a 30 day washout period prior to Day 1 dosing
•cyclosporine, abatacept, etanercept, infliximab or adalimumab require a 60 day washout period prior to Day 1 dosing
•leflunomide requires a 60 day washout period prior to screening, unless the patient has undergone cholestyramine washout at least 30 days prior to Day 1 dosing
•cyclophosphamide requires a 180 day washout period prior to Day 1 dosing

Arms & Interventions

1

R788 50 mg PO bid

Intervention: R788

2

R788 100 mg PO bid

Intervention: R788

3

R788 150 mg PO bid

Intervention: R788

4

Placebo PO bid

Intervention: Placebo

Outcomes

Primary Outcomes

The Primary Efficacy parameter is ACR20 response rate at 3 months post dosing.

Time Frame: 12 weeks

Secondary Outcomes

Disease Activity Score (DAS) at baseline and endpoint(12 Weeks)
ACR 20/50 responses over time(12 weeks)
Mean changes (SDs) from baseline in Swollen Joint Count (28 joint count)(12 Weeks)
Mean changes (SDs) from baseline in Tender Joint Count (28 joint count)(12 Weeks)
Mean changes (SDs) from baseline in Physician global assessment of disease activity by visual analog scale (VAS)(12 Weeks)
Mean changes (SDs) from baseline in Patient global assessment of disease activity by VAS(12 Weeks)
Mean changes (SDs) from baseline in Patient assessment of pain by VAS(12 Weeks)
Mean changes (SDs) from baseline in HAQ-DI(12 Weeks)
Mean changes (SDs) from baseline in CRP(12 Weeks)
The frequency and severity of Liver Function Test abnormalities, especially ALT and alkaline phosphatase(12 Weeks)
The frequency and severity of hematopoietic cytopenias, principally effects on neutrophil, erythrocyte, and lymphocyte counts(12 Weeks)
The frequency and severity of clinically significant adverse events, especially skin rash, postural dizziness, and alterations in blood pressure and other relevant clinical outcomes(12 Weeks)